glycine has been researched along with Amnesia-Memory Loss in 8 studies
Excerpt | Relevance | Reference |
---|---|---|
"We examined the effect of the acetylcholinesterase (AChE) inhibitor, donepezil hydrocloride (DONP), on group II metabotropic glutamate (mGlu) receptor agonist- or antagonist-induced amnesia in the step-through passive avoidance task in male mice." | 7.72 | Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. ( Irifune, M; Nishikawa, T; Ohnishi, Y; Sato, T; Tanaka, K, 2003) |
"We investigated the interrelationship of delayed amnesia, delayed neuronal death and changes in acetylcholine concentration induced by carbon monoxide (CO)-exposure in mice." | 7.68 | Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice. ( Fukuta, T; Inari, K; Ishimaru, H; Kameyama, T; Katoh, A; Murase, K; Nabeshima, T; Ogita, K; Ohtsuka, H; Yoneda, Y, 1991) |
"We examined the effect of the acetylcholinesterase (AChE) inhibitor, donepezil hydrocloride (DONP), on group II metabotropic glutamate (mGlu) receptor agonist- or antagonist-induced amnesia in the step-through passive avoidance task in male mice." | 3.72 | Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice. ( Irifune, M; Nishikawa, T; Ohnishi, Y; Sato, T; Tanaka, K, 2003) |
" Blockade of the metabotropic glutamate receptors by the specific antagonist, (RS)-alpha-Methyl-4-carboxyphenylglycine (500 microM) is shown to induce amnesia during a long-term memory stage in day-old chicks trained on a passive avoidance task, and to have no effect on prelong-term stages." | 3.69 | Blockade of metabotropic glutamate receptors prevents long-term memory consolidation. ( Ng, KT; Rickard, NS, 1995) |
"We investigated the interrelationship of delayed amnesia, delayed neuronal death and changes in acetylcholine concentration induced by carbon monoxide (CO)-exposure in mice." | 3.68 | Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice. ( Fukuta, T; Inari, K; Ishimaru, H; Kameyama, T; Katoh, A; Murase, K; Nabeshima, T; Ogita, K; Ohtsuka, H; Yoneda, Y, 1991) |
" Increasing glycine concentrations in the brain by administration of a glycine prodrug, milacemide, is shown here to enhance performance of a shock-motivated passive avoidance task in rats, and to reverse drug-induced amnesia in a spontaneous alternation paradigm in mice." | 3.67 | Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents. ( Arnolde, SM; Cordi, AA; Handelmann, GE; Mueller, LL; Nevins, ME, 1989) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 1 (12.50) | 18.7374 |
1990's | 4 (50.00) | 18.2507 |
2000's | 1 (12.50) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Solntseva, SV | 1 |
Kozyrev, SA | 1 |
Nikitin, VP | 1 |
Krystal, JH | 1 |
Petrakis, IL | 1 |
Limoncelli, D | 1 |
Nappi, SK | 1 |
Trevisan, L | 1 |
Pittman, B | 1 |
D'Souza, DC | 1 |
Suckow, RF | 1 |
Sato, T | 1 |
Tanaka, K | 1 |
Ohnishi, Y | 1 |
Irifune, M | 1 |
Nishikawa, T | 1 |
Rickard, NS | 1 |
Ng, KT | 1 |
Hölscher, C | 1 |
Maurice, T | 1 |
Lockhart, BP | 1 |
Su, TP | 1 |
Privat, A | 1 |
Nabeshima, T | 1 |
Katoh, A | 1 |
Ishimaru, H | 1 |
Yoneda, Y | 1 |
Ogita, K | 1 |
Murase, K | 1 |
Ohtsuka, H | 1 |
Inari, K | 1 |
Fukuta, T | 1 |
Kameyama, T | 1 |
Handelmann, GE | 1 |
Nevins, ME | 1 |
Mueller, LL | 1 |
Arnolde, SM | 1 |
Cordi, AA | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Glycine and Oral D-Cycloserine in Alcoholic Patients and Healthy Subjects[NCT00635102] | 57 participants (Actual) | Interventional | 1997-10-31 | Completed | |||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.19 | 8 | 9.05 | 5.24 |
Healthy Subjects | 1.30 | 1.667 | 2.08 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.5 | 9 | 10.48 | 5.71 |
Healthy Subjects | 1.82 | 2.17 | 1.67 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 7.27 | 8.5 | 6.67 | 4.76 |
Healthy Subjects | 2.61 | 1.67 | 3.04 | 1.25 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 7.62 | 9.5 | 5 | 7.62 |
Healthy Subjects | 3.04 | 2.5 | 1.67 | 0 |
Alcohol Craving Scale (ACS) Subscale: Desire to drink: Self-report rating scale used to measure desire to drink alcohol (0 No desire to drink alcohol - 100 Definitely desire to drink alcohol) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 9.05 | 9 | 8 | 5.71 |
Healthy Subjects | 1.82 | 2.17 | 2.5 | 2.08 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 8.57 | 9.5 | 9.05 | 6.19 |
Healthy Subjects | 1.14 | 1.67 | 0.42 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 12.38 | 8.95 | 9.5 | 8.57 |
Healthy Subjects | 1.82 | 1.74 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.5 | 10.5 | 9.05 | 6.19 |
Healthy Subjects | 1.36 | 1.74 | 0.42 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.36 | 8.95 | 7.14 | 10.48 |
Healthy Subjects | 1.30 | 1.25 | 0.44 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Discomfort: Self-report rating scale - subscale reflecting expected alcohol-related relief from discomfort (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 8.1 | 12.5 | 7.73 | 8.10 |
Healthy Subjects | 2.61 | 1.67 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.19 | 7 | 8.57 | 7.62 |
Healthy Subjects | 0.87 | 0.83 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 11.43 | 8 | 10.5 | 6.67 |
Healthy Subjects | 0.91 | 0.87 | 0.42 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 5.5 | 8.5 | 8.1 | 6.67 |
Healthy Subjects | 0.46 | 0.87 | 0.83 | 0.83 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 7.73 | 8 | 7.62 | 6.19 |
Healthy Subjects | 0.87 | 0.83 | 1.30 | 0.42 |
Alcohol Craving Scale (ACS) Subscale: Mood improvement : Self-report rating scale used to measure expected alcohol-related mood improvement (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.67 | 10.5 | 6.82 | 8.10 |
Healthy Subjects | 1.74 | 0.42 | 0.42 | 0 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 34.29 | 33.5 | 30.48 | 36.67 |
Healthy Subjects | 98.26 | 99.17 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 32.86 | 36 | 36.5 | 36.67 |
Healthy Subjects | 99.1 | 98.70 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 34 | 39.5 | 25.71 | 37.14 |
Healthy Subjects | 99.1 | 99.13 | 99.17 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 30.46 | 40.5 | 36.67 | 42.86 |
Healthy Subjects | 98.26 | 95 | 99.13 | 99.17 |
Alcohol Craving Scale (ACS) Subscale: Self-report rating scale used to measure reduced control of alcohol (0 Not at all - 100 Definitely) (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 29.05 | 35.5 | 42.27 | 41.43 |
Healthy Subjects | 93.48 | 94.58 | 99.17 | 98.75 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 6.23 | 6.6 | 7.24 | 4.57 |
Healthy Subjects | 7.39 | 3.79 | 6.25 | 3.67 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 3.57 | 4.35 | 4 | 3.71 |
Healthy Subjects | 4.13 | 1.67 | 3.04 | 1.25 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 7.14 | 5.8 | 5.2 | 4.62 |
Healthy Subjects | 10.05 | 5.87 | 7.04 | 3.58 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 5.29 | 5.65 | 8.48 | 4.14 |
Healthy Subjects | 9.64 | 5.83 | 8.54 | 2.54 |
Self-report rating scale used to measure the sedative effects (0 not at all sedated - 70 extremely sedated) of alcohol (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 3.41 | 3.3 | 3.57 | 5 |
Healthy Subjects | 1.91 | 2.75 | 1.83 | 1.88 |
gordon diagnostic system is a continuous performance task (CPT) to measure distractibility - (A-Prime score range 0 minimum - 1 maximum - the higher number the better the performance) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.93 | 0.97 | 0.90 | 0.96 |
Healthy Subjects | 0.1 | 0.1 | 0.1 | 0.1 |
gordon diagnostic system is a continuous performance task (CPT) to measure Vigilance - (A-Prime score range 0 minimum - 1 maximum - The higher number the better the performance) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.98 | 0.1 | 0.1 | 0.99 |
Healthy Subjects | 0.1 | 0.1 | 0.1 | 0.1 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (delay recall - 30 minutes after Trials 1-3 were given) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 90 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 5.1 | 7.75 | 6.29 | 8.25 |
Healthy Subjects | 9.7 | 10.87 | 10.21 | 11.38 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 1
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 5.29 | 6.05 | 5.48 | 5.95 |
Healthy Subjects | 7.09 | 8.52 | 7.75 | 8.2 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 2
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 7.67 | 8.45 | 7.1 | 8.67 |
Healthy Subjects | 10.09 | 11.09 | 10.5 | 10.96 |
Hopkins Verbal Learning Task (HVLT) - measures verbal memory and hippocampus function. (Three immediate recall trials) (0 No words recalled - 12 all words recalled) (NCT00635102)
Timeframe: 60 minutes - Trial 3
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 8 | 9.2 | 8.48 | 9.24 |
Healthy Subjects | 10.57 | 11.48 | 11.17 | 11.67 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 120 minutes
Intervention | Number of Drinks Felt Consumed (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0 | 0.1 | 0.05 | 0 |
Healthy Subjects | 0.13 | 0.21 | 0 | 0.04 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 30 minutes
Intervention | Number of Drinks Felt Consumed (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.38 | 0.20 | 0.38 | 0.24 |
Healthy Subjects | 0.68 | 0.13 | 0.38 | 0.04 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 60 minutes
Intervention | Number of Drinks Felt Consumed (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.05 | 0.5 | 0.86 | 0.05 |
Healthy Subjects | 1.24 | 0.4 | 0.83 | 0.2 |
The Number of Drinks Scale asks subjects to report on the number of alcoholic drinks they felt they had consumed. (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | drinks felt consumed (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.50 | 0.30 | 0.24 | 0.05 |
Healthy Subjects | 0.70 | 0.25 | 0.75 | 0.22 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.8 | 0.55 | 0.76 | 0.24 |
Healthy Subjects | 0.35 | 0.21 | 0.29 | 0.25 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.48 | 0.65 | 0.48 | 0.52 |
Healthy Subjects | 1.05 | 0.30 | 0.79 | 0.25 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.52 | 0.8 | 0.6 | 0.19 |
Healthy Subjects | 0.91 | 0.22 | 0.71 | 0.17 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.64 | 0.68 | 0.48 | 0.38 |
Healthy Subjects | 0.82 | 0.33 | 0.96 | 0.61 |
Visual Analog Scales (VAS): Self-report rating scale used to measure high (0 not at all - 7 extremely) (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.32 | 0.5 | 0.76 | 0.48 |
Healthy Subjects | 0.22 | 0.22 | 0.25 | 0.25 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: Baseline
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.18 | 0.25 | 0.10 | 0.24 |
Healthy Subjects | 0.05 | 0.04 | 0.04 | 0 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 120 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.43 | 0.3 | 0.57 | 0.10 |
Healthy Subjects | 0.41 | 0.09 | 0.29 | 0.33 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 30 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.57 | 0.60 | 1.05 | 0.43 |
Healthy Subjects | 1.81 | 0.71 | 1.21 | 0.13 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 60 minutes
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.67 | 0.75 | 0.81 | 0.24 |
Healthy Subjects | 1.81 | 0.70 | 1.46 | 0.13 |
Visual Analog Scales of Similarity to Alcohol data using the Likert scale (0 Not at all similar to alcohol -7 Extremely similar to alcohol) evaluating the similarity of drug effects to alcohol (NCT00635102)
Timeframe: 60 minutes prior to Glycine infusion
Intervention | units on a scale (Mean) | |||
---|---|---|---|---|
Glycine / Cycloserine | Glycine / Placebo | Placebo / Cycloserine | Placebo / Placebo | |
Alcoholic Subjects | 0.77 | 0.65 | 0.48 | 0.43 |
Healthy Subjects | 1.41 | 0.67 | 1.17 | .025 |
1 trial available for glycine and Amnesia-Memory Loss
Article | Year |
---|---|
Characterization of the interactive effects of glycine and D-cycloserine in men: further evidence for enhanced NMDA receptor function associated with human alcohol dependence.
Topics: Adult; Alcoholism; Amnesia; Antimetabolites; Arousal; Chromatography, Liquid; Cognition; Cycloserine | 2011 |
7 other studies available for glycine and Amnesia-Memory Loss
Article | Year |
---|---|
A Study of the Participation of NMDA Glutamate Receptors in the Mechanisms of Specific Anterograde Amnesia Reversion.
Topics: Amnesia; Amnesia, Anterograde; Animals; Avoidance Learning; Conditioning, Classical; Cycloserine; Di | 2020 |
Effect of donepezil on group II mGlu receptor agonist- or antagonist-induced amnesia on passive avoidance in mice.
Topics: Amino Acids; Amnesia; Animals; Avoidance Learning; Cholinesterase Inhibitors; Cyclopropanes; Donepez | 2003 |
Blockade of metabotropic glutamate receptors prevents long-term memory consolidation.
Topics: Amnesia; Animals; Avoidance Learning; Discrimination, Psychological; Dose-Response Relationship, Dru | 1995 |
Inhibitors of metabotropic glutamate receptors produce amnestic effects in chicks.
Topics: Aminobutyrates; Amnesia; Animals; Avoidance Learning; Benzoates; Chickens; Cycloleucine; Cyclopropan | 1994 |
Reversion of beta 25-35-amyloid peptide-induced amnesia by NMDA receptor-associated glycine site agonists.
Topics: Acetamides; Amnesia; Amyloid beta-Peptides; Animals; Antimetabolites; Avoidance Learning; Behavior, | 1996 |
Carbon monoxide-induced delayed amnesia, delayed neuronal death and change in acetylcholine concentration in mice.
Topics: Acetylcholine; Amnesia; Animals; Binding Sites; Brain; Carbon Monoxide; Cell Survival; Choline; Glut | 1991 |
Milacemide, a glycine prodrug, enhances performance of learning tasks in normal and amnestic rodents.
Topics: Acetamides; Amnesia; Animals; Avoidance Learning; Benzamides; Exploratory Behavior; Glycine; Male; M | 1989 |